Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AgomAb Therapeutics NVAGMB +1.96%14 3-1 Month Momentum % is 13.21% as of Aug. 27, 2026. GuruFocus rates AGMB with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 1,384 Biotechnology companies, AgomAb Therapeutics NV ranks better than 83.09% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-27), AgomAb Therapeutics NV's 3-1 Month Momentum % is 13.21%.
The industry rank for AgomAb Therapeutics NV's 3-1 Month Momentum % or its related term are showing as below:
AGMB's 3-1 Month Momentum % is ranked better than 83.09% of 1384
companies
in the Biotechnology industry
Industry Median: -9.34
vs AGMB: 13.21
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
AgomAb Therapeutics NV 3-1 Month Momentum % Related Terms
AGMB vs CRMD, RGNX, MDXG: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, AgomAb Therapeutics NV's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AgomAb Therapeutics NV 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AgomAb Therapeutics NV's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where AgomAb Therapeutics NV's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AgomAb Therapeutics NV (AGMB) has a 3-1 Month Momentum % of 13.21% as of Aug. 27, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on AgomAb Therapeutics NV and its competitors. According to the industry distribution chart, AgomAb Therapeutics NV ranks #234 out of 1384 companies in the Biotechnology industry, placing it in the top 16.9%.
Is AgomAb Therapeutics NV's 3-1 Month Momentum % too high?
AgomAb Therapeutics NV's current 3-1 Month Momentum % is 13.21%. Based on the distribution chart, AgomAb Therapeutics NV ranks #234 out of 1384 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, AgomAb Therapeutics NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does AgomAb Therapeutics NV's 3-1 Month Momentum % compare to CRMD and RGNX?
According to the Biotechnology industry distribution chart, AgomAb Therapeutics NV ranks #234 out of 1384 companies for 3-1 Month Momentum %. This places AgomAb Therapeutics NV in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on AgomAb Therapeutics NV and its competitors. AgomAb Therapeutics NV's current 3-1 Month Momentum % is 13.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AgomAb Therapeutics NV stock overvalued right now?
AgomAb Therapeutics NV (AGMB) has a current 3-1 Month Momentum % of 13.21%. The current 3-1 Month Momentum % is 13.21%. AgomAb Therapeutics NV's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For AgomAb Therapeutics NV (AGMB), the current 3-1 Month Momentum % is 13.21% as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
14GF Score
Get the complete analysis for AGMB
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AGMB has been successfully added to your 
